^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MTAP deletion + KRAS G12C

    i
    Other names: MTAP, Methylthioadenosine Phosphorylase, S-Methyl-5'-Thioadenosine Phosphorylase, MSAP, 5’-Methylthioadenosine Phosphorylase, MTA Phosphorylase, MTAPase, C86fus, Epididymis Secretory Sperm Binding Protein, Epididymis Luminal Protein 249, MeSAdo Phosphorylase, HEL-249, DMSMFH, DMSFH, LGMBF, BDMF, KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845; 4507
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    almost3years
    Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model (ESMO-TAT 2022)
    These data suggest that treatment of KRASG12C-mutant lung adenocarcinoma with TNG908 and a KRASG12C inhibitor may be of clinical benefit in lung cancers with concurrent MTAP deletion and KRASG12C mutation.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • MTAP (Methylthioadenosine Phosphorylase) • PRMT5 (Protein Arginine Methyltransferase 5)
    |
    KRAS mutation • KRAS G12C • MTAP deletion • KRAS deletion • MTAP deletion + KRAS G12C
    |
    Lumakras (sotorasib) • TNG908